These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 32127390)
1. Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer. Umer BA; Noyce RS; Franczak BC; Shenouda MM; Kelly RG; Favis NA; Desaulniers M; Baldwin TA; Hitt MM; Evans DH Cancer Immunol Res; 2020 May; 8(5):618-631. PubMed ID: 32127390 [TBL] [Abstract][Full Text] [Related]
2. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy. Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995 [TBL] [Abstract][Full Text] [Related]
3. A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses. Rojas JJ; Van Hoecke L; Conesa M; Bueno-Merino C; Del Canizo A; Riederer S; Barcia M; Brosinski K; Lehmann MH; Volz A; Saelens X; Sutter G Mol Ther; 2024 Jul; 32(7):2406-2422. PubMed ID: 38734899 [TBL] [Abstract][Full Text] [Related]
4. Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice. Chen NG; Yu YA; Zhang Q; Szalay AA J Transl Med; 2011 Sep; 9():164. PubMed ID: 21951588 [TBL] [Abstract][Full Text] [Related]
5. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109 [TBL] [Abstract][Full Text] [Related]
7. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846 [No Abstract] [Full Text] [Related]
8. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic vaccinia virus and cancer immunotherapy. Xu L; Sun H; Lemoine NR; Xuan Y; Wang P Front Immunol; 2023; 14():1324744. PubMed ID: 38283361 [TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644 [TBL] [Abstract][Full Text] [Related]
11. Deletion of Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079 [TBL] [Abstract][Full Text] [Related]
12. IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer. Deng L; Yang X; Fan J; Ding Y; Peng Y; Xu D; Huang B; Hu Z Oncol Res; 2021 Mar; 28(6):579-590. PubMed ID: 32641200 [TBL] [Abstract][Full Text] [Related]
13. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. Worschech A; Chen N; Yu YA; Zhang Q; Pos Z; Weibel S; Raab V; Sabatino M; Monaco A; Liu H; Monsurró V; Buller RM; Stroncek DF; Wang E; Szalay AA; Marincola FM BMC Genomics; 2009 Jul; 10():301. PubMed ID: 19583830 [TBL] [Abstract][Full Text] [Related]
14. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576 [TBL] [Abstract][Full Text] [Related]
15. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. de Vries CR; Monken CE; Lattime EC Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483 [TBL] [Abstract][Full Text] [Related]
16. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer. Yoo SY; Bang SY; Jeong SN; Kang DH; Heo J Oncotarget; 2016 Mar; 7(13):16479-89. PubMed ID: 26918725 [TBL] [Abstract][Full Text] [Related]
17. Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. Weibel S; Raab V; Yu YA; Worschech A; Wang E; Marincola FM; Szalay AA BMC Cancer; 2011 Feb; 11():68. PubMed ID: 21320309 [TBL] [Abstract][Full Text] [Related]
19. A new oncolytic Ahmed J; Chard LS; Yuan M; Wang J; Howells A; Li Y; Li H; Zhang Z; Lu S; Gao D; Wang P; Chu Y; Al Yaghchi C; Schwartz J; Alusi G; Lemoine N; Wang Y J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217766 [TBL] [Abstract][Full Text] [Related]
20. Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus. Ferguson MS; Chard Dunmall LS; Gangeswaran R; Marelli G; Tysome JR; Burns E; Whitehead MA; Aksoy E; Alusi G; Hiley C; Ahmed J; Vanhaesebroeck B; Lemoine NR; Wang Y Mol Ther; 2020 May; 28(5):1263-1275. PubMed ID: 32145202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]